High	O
concordance	O
of	O
findings	B:C0243095
obtained	O
from	O
transgluteal	O
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
-	O
and	O
transrectal	O
ultrasonography	I:C0373345
-	O
guided	O
biopsy	I:C0456900
as	O
compared	O
with	O
prostatectomy	O
specimens	O
.	O

High	O
concordance	O
of	O
findings	O
obtained	O
from	O
transgluteal	B:C0444462
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
-	O
and	O
transrectal	O
ultrasonography	I:C0373345
-	O
guided	O
biopsy	I:C0456900
as	O
compared	O
with	O
prostatectomy	O
specimens	O
.	O

High	O
concordance	O
of	O
findings	O
obtained	O
from	O
transgluteal	O
magnetic	B:C0024485
resonance	I:C0024485
imaging	I:C0024485
-	O
and	O
transrectal	O
ultrasonography	I:C0373345
-	O
guided	O
biopsy	I:C0456900
as	O
compared	O
with	O
prostatectomy	O
specimens	O
.	O

High	O
concordance	O
of	O
findings	O
obtained	O
from	O
transgluteal	O
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
-	O
and	O
transrectal	B:C0373345
ultrasonography	I:C0373345
-	O
guided	O
biopsy	I:C0456900
as	O
compared	O
with	O
prostatectomy	O
specimens	O
.	O

High	O
concordance	O
of	O
findings	O
obtained	O
from	O
transgluteal	O
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
-	O
and	O
transrectal	O
ultrasonography	I:C0373345
-	O
guided	B:C0456900
biopsy	I:C0456900
as	O
compared	O
with	O
prostatectomy	O
specimens	O
.	O

High	O
concordance	O
of	O
findings	O
obtained	O
from	O
transgluteal	O
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
-	O
and	O
transrectal	O
ultrasonography	I:C0373345
-	O
guided	O
biopsy	I:C0456900
as	O
compared	O
with	O
prostatectomy	B:C0033573
specimens	O
.	O

To	O
determine	O
the	O
utility	O
of	O
our	O
transgluteal	B:C0444462
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
(	O
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
)	O
-	O
guided	O
prostate	I:C0456852
biopsy	I:C0456852
approach	O
.	O

To	O
determine	O
the	O
utility	O
of	O
our	O
transgluteal	O
magnetic	B:C0024485
resonance	I:C0024485
imaging	I:C0024485
(	O
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
)	O
-	O
guided	O
prostate	I:C0456852
biopsy	I:C0456852
approach	O
.	O

To	O
determine	O
the	O
utility	O
of	O
our	O
transgluteal	O
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
(	O
magnetic	B:C0024485
resonance	I:C0024485
imaging	I:C0024485
)	O
-	O
guided	O
prostate	I:C0456852
biopsy	I:C0456852
approach	O
.	O

To	O
determine	O
the	O
utility	O
of	O
our	O
transgluteal	O
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
(	O
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
)	O
-	O
guided	B:C0456852
prostate	I:C0456852
biopsy	I:C0456852
approach	O
.	O

A	O
total	O
of	O
960	O
biopsy	B:C0005558
series	O
,	O
taken	O
within	O
the	O
period	O
of	O
1	O
year	O
,	O
were	O
evaluated	O
,	O
including	O
301	O
MRI	O
-	I:C0456854
guided	I:C0456854
and	O
659	O
transrectal	O
ultrasonography	I:C0373345
(	O
transrectal	O
ultrasonography	I:C0373345
)	O
-	O
guided	O
biopsies	I:C0456900
.	O

A	O
total	O
of	O
960	O
biopsy	O
series	O
,	O
taken	O
within	O
the	O
period	O
of	O
1	O
year	O
,	O
were	O
evaluated	B:C0220825
,	O
including	O
301	O
MRI	O
-	I:C0456854
guided	I:C0456854
and	O
659	O
transrectal	O
ultrasonography	I:C0373345
(	O
transrectal	O
ultrasonography	I:C0373345
)	O
-	O
guided	O
biopsies	I:C0456900
.	O

A	O
total	O
of	O
960	O
biopsy	O
series	O
,	O
taken	O
within	O
the	O
period	O
of	O
1	O
year	O
,	O
were	O
evaluated	O
,	O
including	O
301	O
MRI	B:C0456854
-	I:C0456854
guided	I:C0456854
and	O
659	O
transrectal	O
ultrasonography	I:C0373345
(	O
transrectal	O
ultrasonography	I:C0373345
)	O
-	O
guided	O
biopsies	I:C0456900
.	O

A	O
total	O
of	O
960	O
biopsy	O
series	O
,	O
taken	O
within	O
the	O
period	O
of	O
1	O
year	O
,	O
were	O
evaluated	O
,	O
including	O
301	O
MRI	O
-	I:C0456854
guided	I:C0456854
and	O
659	O
transrectal	B:C0373345
ultrasonography	I:C0373345
(	O
transrectal	O
ultrasonography	I:C0373345
)	O
-	O
guided	O
biopsies	I:C0456900
.	O

A	O
total	O
of	O
960	O
biopsy	O
series	O
,	O
taken	O
within	O
the	O
period	O
of	O
1	O
year	O
,	O
were	O
evaluated	O
,	O
including	O
301	O
MRI	O
-	I:C0456854
guided	I:C0456854
and	O
659	O
transrectal	O
ultrasonography	I:C0373345
(	O
transrectal	B:C0373345
ultrasonography	I:C0373345
)	O
-	O
guided	O
biopsies	I:C0456900
.	O

A	O
total	O
of	O
960	O
biopsy	O
series	O
,	O
taken	O
within	O
the	O
period	O
of	O
1	O
year	O
,	O
were	O
evaluated	O
,	O
including	O
301	O
MRI	O
-	I:C0456854
guided	I:C0456854
and	O
659	O
transrectal	O
ultrasonography	I:C0373345
(	O
transrectal	O
ultrasonography	I:C0373345
)	O
-	O
guided	B:C0456900
biopsies	I:C0456900
.	O

The	O
positivity	B:C1446409
rate	O
and	O
proportion	O
of	O
high	O
grade	I:C1962917
cancers	O
were	O
significantly	O
higher	O
in	O
MRI	O
-	I:C0456854
guided	I:C0456854
than	O
in	O
transrectal	O
ultrasonography	I:C0373345
-	O
guided	O
biopsies	I:C0456900
.	O

The	O
positivity	O
rate	O
and	O
proportion	O
of	O
high	B:C1962917
grade	I:C1962917
cancers	O
were	O
significantly	O
higher	O
in	O
MRI	O
-	I:C0456854
guided	I:C0456854
than	O
in	O
transrectal	O
ultrasonography	I:C0373345
-	O
guided	O
biopsies	I:C0456900
.	O

The	O
positivity	O
rate	O
and	O
proportion	O
of	O
high	O
grade	I:C1962917
cancers	B:C0006826
were	O
significantly	O
higher	O
in	O
MRI	O
-	I:C0456854
guided	I:C0456854
than	O
in	O
transrectal	O
ultrasonography	I:C0373345
-	O
guided	O
biopsies	I:C0456900
.	O

The	O
positivity	O
rate	O
and	O
proportion	O
of	O
high	O
grade	I:C1962917
cancers	O
were	O
significantly	O
higher	O
in	O
MRI	B:C0456854
-	I:C0456854
guided	I:C0456854
than	O
in	O
transrectal	O
ultrasonography	I:C0373345
-	O
guided	O
biopsies	I:C0456900
.	O

The	O
positivity	O
rate	O
and	O
proportion	O
of	O
high	O
grade	I:C1962917
cancers	O
were	O
significantly	O
higher	O
in	O
MRI	O
-	I:C0456854
guided	I:C0456854
than	O
in	O
transrectal	B:C0373345
ultrasonography	I:C0373345
-	O
guided	O
biopsies	I:C0456900
.	O

The	O
positivity	O
rate	O
and	O
proportion	O
of	O
high	O
grade	I:C1962917
cancers	O
were	O
significantly	O
higher	O
in	O
MRI	O
-	I:C0456854
guided	I:C0456854
than	O
in	O
transrectal	O
ultrasonography	I:C0373345
-	O
guided	B:C0456900
biopsies	I:C0456900
.	O

Of	O
301	O
MRI	B:C0456854
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
,	O
65.4	O
%	O
contained	O
cancer	O
while	O
57.2	O
%	O
of	O
659	O
transrectal	O
ultrasonography	I:C0373345
biopsies	O
contained	O
cancer	O
(	O
P	O
=	O
0.016	O
)	O
.	O

Of	O
301	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
,	O
65.4	O
%	O
contained	O
cancer	B:C0006826
while	O
57.2	O
%	O
of	O
659	O
transrectal	O
ultrasonography	I:C0373345
biopsies	O
contained	O
cancer	O
(	O
P	O
=	O
0.016	O
)	O
.	O

Of	O
301	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
,	O
65.4	O
%	O
contained	O
cancer	O
while	O
57.2	O
%	O
of	O
659	O
transrectal	B:C0373345
ultrasonography	I:C0373345
biopsies	O
contained	O
cancer	O
(	O
P	O
=	O
0.016	O
)	O
.	O

Of	O
301	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
,	O
65.4	O
%	O
contained	O
cancer	O
while	O
57.2	O
%	O
of	O
659	O
transrectal	O
ultrasonography	I:C0373345
biopsies	B:C0456900
contained	O
cancer	O
(	O
P	O
=	O
0.016	O
)	O
.	O

Of	O
301	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
,	O
65.4	O
%	O
contained	O
cancer	O
while	O
57.2	O
%	O
of	O
659	O
transrectal	O
ultrasonography	I:C0373345
biopsies	O
contained	O
cancer	B:C0006826
(	O
P	O
=	O
0.016	O
)	O
.	O

Gleason	B:C3203027
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
disease	O
was	O
observed	O
in	O
16.8	O
%	O
of	O
197	O
MRI	O
-	I:C0456854
guided	I:C0456854
and	O
in	O
36.1	O
%	O
of	O
377	O
transrectal	O
ultrasonography	I:C0373345
-	O
guided	O
biopsies	I:C0456900
(	O
P	O
<	O
0.001	O
)	O
.	O

Gleason	O
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
disease	O
was	O
observed	O
in	O
16.8	O
%	O
of	O
197	O
MRI	B:C0456854
-	I:C0456854
guided	I:C0456854
and	O
in	O
36.1	O
%	O
of	O
377	O
transrectal	O
ultrasonography	I:C0373345
-	O
guided	O
biopsies	I:C0456900
(	O
P	O
<	O
0.001	O
)	O
.	O

Gleason	O
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
disease	O
was	O
observed	O
in	O
16.8	O
%	O
of	O
197	O
MRI	O
-	I:C0456854
guided	I:C0456854
and	O
in	O
36.1	O
%	O
of	O
377	O
transrectal	B:C0373345
ultrasonography	I:C0373345
-	O
guided	O
biopsies	I:C0456900
(	O
P	O
<	O
0.001	O
)	O
.	O

Gleason	O
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
disease	O
was	O
observed	O
in	O
16.8	O
%	O
of	O
197	O
MRI	O
-	I:C0456854
guided	I:C0456854
and	O
in	O
36.1	O
%	O
of	O
377	O
transrectal	O
ultrasonography	I:C0373345
-	O
guided	B:C0456900
biopsies	I:C0456900
(	O
P	O
<	O
0.001	O
)	O
.	O

There	O
was	O
also	O
a	O
markedly	O
higher	O
quantity	O
of	O
cancer	B:C0027656
tissue	I:C0027656
in	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
.	O

There	O
was	O
also	O
a	O
markedly	O
higher	O
quantity	O
of	O
cancer	O
tissue	I:C0027656
in	O
MRI	B:C0456854
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
.	O

In	O
all	O
cancers	B:C0006826
,	O
the	O
mean	O
cancer	O
surface	O
area	I:C0205146
was	O
64.8	O
±	O
51.6	O
mm	O
(	O
2	O
)	O
in	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
as	O
compared	O
with	O
23.0	O
±	O
31.4	O
mm	O
(	O
2	O
)	O
in	O
non-MRI	O
-	O
guided	O
biopsies	O
(	O
P	O
<	O
0.001	O
)	O
.	O

In	O
all	O
cancers	O
,	O
the	O
mean	O
cancer	B:C0006826
surface	O
area	I:C0205146
was	O
64.8	O
±	O
51.6	O
mm	O
(	O
2	O
)	O
in	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
as	O
compared	O
with	O
23.0	O
±	O
31.4	O
mm	O
(	O
2	O
)	O
in	O
non-MRI	O
-	O
guided	O
biopsies	O
(	O
P	O
<	O
0.001	O
)	O
.	O

In	O
all	O
cancers	O
,	O
the	O
mean	O
cancer	O
surface	B:C0205146
area	I:C0205146
was	O
64.8	O
±	O
51.6	O
mm	O
(	O
2	O
)	O
in	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
as	O
compared	O
with	O
23.0	O
±	O
31.4	O
mm	O
(	O
2	O
)	O
in	O
non-MRI	O
-	O
guided	O
biopsies	O
(	O
P	O
<	O
0.001	O
)	O
.	O

In	O
all	O
cancers	O
,	O
the	O
mean	O
cancer	O
surface	O
area	I:C0205146
was	O
64.8	O
±	O
51.6	O
mm	O
(	O
2	O
)	O
in	O
MRI	B:C0456854
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
as	O
compared	O
with	O
23.0	O
±	O
31.4	O
mm	O
(	O
2	O
)	O
in	O
non-MRI	O
-	O
guided	O
biopsies	O
(	O
P	O
<	O
0.001	O
)	O
.	O

With	O
respect	O
to	O
the	O
tissue	B:C0027656
quantity	O
,	O
superiority	O
of	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsy	I:C0456854
was	O
highest	O
in	O
Gleason	O
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
cancers	O
(	O
20.9	O
±	O
27.9	O
vs	O
5.1	O
±	O
10.2	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
and	O
in	O
Gleason	O
grade	I:C3203027
3	O
+	O
4	O
=	O
7	O
cancers	O
(	O
59.7	O
±	O
38.0	O
vs	O
17.7	O
±	O
18.4	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
.	O

With	O
respect	O
to	O
the	O
tissue	O
quantity	O
,	O
superiority	B:C1282910
of	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsy	I:C0456854
was	O
highest	O
in	O
Gleason	O
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
cancers	O
(	O
20.9	O
±	O
27.9	O
vs	O
5.1	O
±	O
10.2	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
and	O
in	O
Gleason	O
grade	I:C3203027
3	O
+	O
4	O
=	O
7	O
cancers	O
(	O
59.7	O
±	O
38.0	O
vs	O
17.7	O
±	O
18.4	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
.	O

With	O
respect	O
to	O
the	O
tissue	O
quantity	O
,	O
superiority	O
of	O
MRI	B:C0456854
-	I:C0456854
guided	I:C0456854
biopsy	I:C0456854
was	O
highest	O
in	O
Gleason	O
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
cancers	O
(	O
20.9	O
±	O
27.9	O
vs	O
5.1	O
±	O
10.2	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
and	O
in	O
Gleason	O
grade	I:C3203027
3	O
+	O
4	O
=	O
7	O
cancers	O
(	O
59.7	O
±	O
38.0	O
vs	O
17.7	O
±	O
18.4	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
.	O

With	O
respect	O
to	O
the	O
tissue	O
quantity	O
,	O
superiority	O
of	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsy	I:C0456854
was	O
highest	O
in	O
Gleason	B:C3203027
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
cancers	O
(	O
20.9	O
±	O
27.9	O
vs	O
5.1	O
±	O
10.2	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
and	O
in	O
Gleason	O
grade	I:C3203027
3	O
+	O
4	O
=	O
7	O
cancers	O
(	O
59.7	O
±	O
38.0	O
vs	O
17.7	O
±	O
18.4	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
.	O

With	O
respect	O
to	O
the	O
tissue	O
quantity	O
,	O
superiority	O
of	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsy	I:C0456854
was	O
highest	O
in	O
Gleason	O
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
cancers	B:C0006826
(	O
20.9	O
±	O
27.9	O
vs	O
5.1	O
±	O
10.2	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
and	O
in	O
Gleason	O
grade	I:C3203027
3	O
+	O
4	O
=	O
7	O
cancers	O
(	O
59.7	O
±	O
38.0	O
vs	O
17.7	O
±	O
18.4	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
.	O

With	O
respect	O
to	O
the	O
tissue	O
quantity	O
,	O
superiority	O
of	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsy	I:C0456854
was	O
highest	O
in	O
Gleason	O
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
cancers	O
(	O
20.9	O
±	O
27.9	O
vs	O
5.1	O
±	O
10.2	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
and	O
in	O
Gleason	B:C3203027
grade	I:C3203027
3	O
+	O
4	O
=	O
7	O
cancers	O
(	O
59.7	O
±	O
38.0	O
vs	O
17.7	O
±	O
18.4	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
.	O

With	O
respect	O
to	O
the	O
tissue	O
quantity	O
,	O
superiority	O
of	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsy	I:C0456854
was	O
highest	O
in	O
Gleason	O
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
cancers	O
(	O
20.9	O
±	O
27.9	O
vs	O
5.1	O
±	O
10.2	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
and	O
in	O
Gleason	O
grade	I:C3203027
3	O
+	O
4	O
=	O
7	O
cancers	B:C0006826
(	O
59.7	O
±	O
38.0	O
vs	O
17.7	O
±	O
18.4	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Comparison	O
of	O
biopsy	B:C0005558
Gleason	O
grades	I:C3203027
with	O
findings	O
in	O
prostatectomy	O
specimens	O
was	O
possible	O
in	O
80	O
patients	O
with	O
MRI	O
-	I:C0456854
guided	I:C0456854
and	O
in	O
170	O
patients	O
with	O
non-MRI	O
-	O
guided	O
biopsies	O
.	O

Comparison	O
of	O
biopsy	O
Gleason	B:C3203027
grades	I:C3203027
with	O
findings	O
in	O
prostatectomy	O
specimens	O
was	O
possible	O
in	O
80	O
patients	O
with	O
MRI	O
-	I:C0456854
guided	I:C0456854
and	O
in	O
170	O
patients	O
with	O
non-MRI	O
-	O
guided	O
biopsies	O
.	O

Comparison	O
of	O
biopsy	O
Gleason	O
grades	I:C3203027
with	O
findings	B:C0243095
in	O
prostatectomy	O
specimens	O
was	O
possible	O
in	O
80	O
patients	O
with	O
MRI	O
-	I:C0456854
guided	I:C0456854
and	O
in	O
170	O
patients	O
with	O
non-MRI	O
-	O
guided	O
biopsies	O
.	O

Comparison	O
of	O
biopsy	O
Gleason	O
grades	I:C3203027
with	O
findings	O
in	O
prostatectomy	B:C0033573
specimens	O
was	O
possible	O
in	O
80	O
patients	O
with	O
MRI	O
-	I:C0456854
guided	I:C0456854
and	O
in	O
170	O
patients	O
with	O
non-MRI	O
-	O
guided	O
biopsies	O
.	O

Comparison	O
of	O
biopsy	O
Gleason	O
grades	I:C3203027
with	O
findings	O
in	O
prostatectomy	O
specimens	O
was	O
possible	O
in	O
80	O
patients	O
with	O
MRI	B:C0456854
-	I:C0456854
guided	I:C0456854
and	O
in	O
170	O
patients	O
with	O
non-MRI	O
-	O
guided	O
biopsies	O
.	O

This	O
comparison	O
showed	O
a	O
very	O
high	O
but	O
almost	O
identical	O
concordance	O
of	O
transrectal	B:C0373345
ultrasonography	I:C0373345
-	O
and	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
with	O
the	O
prostatectomy	O
specimen	O
findings	O
.	O

This	O
comparison	O
showed	O
a	O
very	O
high	O
but	O
almost	O
identical	O
concordance	O
of	O
transrectal	O
ultrasonography	I:C0373345
-	O
and	O
MRI	B:C0456854
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
with	O
the	O
prostatectomy	O
specimen	O
findings	O
.	O

This	O
comparison	O
showed	O
a	O
very	O
high	O
but	O
almost	O
identical	O
concordance	O
of	O
transrectal	O
ultrasonography	I:C0373345
-	O
and	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
with	O
the	O
prostatectomy	B:C0033573
specimen	O
findings	O
.	O

This	O
comparison	O
showed	O
a	O
very	O
high	O
but	O
almost	O
identical	O
concordance	O
of	O
transrectal	O
ultrasonography	I:C0373345
-	O
and	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
with	O
the	O
prostatectomy	O
specimen	O
findings	B:C0243095
.	O

With	O
both	O
approaches	O
,	O
undetected	B:C0442737
high	O
-	I:C1512441
risk	I:C1512441
cancers	I:C1512441
were	O
present	O
in	O
~	O
10	O
%	O
of	O
patients	O
with	O
low	O
-	O
risk	O
biopsy	O
results	O
.	O

With	O
both	O
approaches	O
,	O
undetected	O
high	B:C1512441
-	I:C1512441
risk	I:C1512441
cancers	I:C1512441
were	O
present	O
in	O
~	O
10	O
%	O
of	O
patients	O
with	O
low	O
-	O
risk	O
biopsy	O
results	O
.	O

With	O
both	O
approaches	O
,	O
undetected	O
high	O
-	I:C1512441
risk	I:C1512441
cancers	I:C1512441
were	O
present	B:C0150312
in	O
~	O
10	O
%	O
of	O
patients	O
with	O
low	O
-	O
risk	O
biopsy	O
results	O
.	O

With	O
both	O
approaches	O
,	O
undetected	O
high	O
-	I:C1512441
risk	I:C1512441
cancers	I:C1512441
were	O
present	O
in	O
~	O
10	O
%	O
of	O
patients	O
with	O
low	O
-	O
risk	O
biopsy	B:C0005558
results	O
.	O

With	O
both	O
approaches	O
,	O
undetected	O
high	O
-	I:C1512441
risk	I:C1512441
cancers	I:C1512441
were	O
present	O
in	O
~	O
10	O
%	O
of	O
patients	O
with	O
low	O
-	O
risk	O
biopsy	O
results	B:C0456984
.	O

A	O
significant	O
difference	O
was	O
observed	O
,	O
however	O
,	O
in	O
the	O
proportion	O
of	O
patients	O
who	O
had	O
clinically	O
insignificant	B:C1273937
cancers	O
and	O
who	O
underwent	O
surgery	O
.	O

A	O
significant	O
difference	O
was	O
observed	O
,	O
however	O
,	O
in	O
the	O
proportion	O
of	O
patients	O
who	O
had	O
clinically	O
insignificant	O
cancers	B:C0006826
and	O
who	O
underwent	O
surgery	O
.	O

A	O
significant	O
difference	O
was	O
observed	O
,	O
however	O
,	O
in	O
the	O
proportion	O
of	O
patients	O
who	O
had	O
clinically	O
insignificant	O
cancers	O
and	O
who	O
underwent	O
surgery	B:C0543467
.	O

The	O
proportion	O
of	O
patients	O
with	O
Gleason	B:C3203027
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
carcinoma	O
in	O
their	O
prostatectomy	O
specimen	O
was	O
11.2	O
%	O
in	O
the	O
post	O
-	O
transrectal	O
ultrasonography	I:C0373345
biopsy	O
cohort	O
,	O
but	O
only	O
2.5	O
%	O
in	O
the	O
post	O
-	O
MRI	O
biopsy	I:C0456854
cohort	O
(	O
P	O
=	O
0.021	O
)	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
Gleason	O
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
carcinoma	B:C0007097
in	O
their	O
prostatectomy	O
specimen	O
was	O
11.2	O
%	O
in	O
the	O
post	O
-	O
transrectal	O
ultrasonography	I:C0373345
biopsy	O
cohort	O
,	O
but	O
only	O
2.5	O
%	O
in	O
the	O
post	O
-	O
MRI	O
biopsy	I:C0456854
cohort	O
(	O
P	O
=	O
0.021	O
)	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
Gleason	O
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
carcinoma	O
in	O
their	O
prostatectomy	B:C0033573
specimen	O
was	O
11.2	O
%	O
in	O
the	O
post	O
-	O
transrectal	O
ultrasonography	I:C0373345
biopsy	O
cohort	O
,	O
but	O
only	O
2.5	O
%	O
in	O
the	O
post	O
-	O
MRI	O
biopsy	I:C0456854
cohort	O
(	O
P	O
=	O
0.021	O
)	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
Gleason	O
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
carcinoma	O
in	O
their	O
prostatectomy	O
specimen	O
was	O
11.2	O
%	O
in	O
the	O
post	O
-	O
transrectal	B:C0373345
ultrasonography	I:C0373345
biopsy	O
cohort	O
,	O
but	O
only	O
2.5	O
%	O
in	O
the	O
post	O
-	O
MRI	O
biopsy	I:C0456854
cohort	O
(	O
P	O
=	O
0.021	O
)	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
Gleason	O
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
carcinoma	O
in	O
their	O
prostatectomy	O
specimen	O
was	O
11.2	O
%	O
in	O
the	O
post	O
-	O
transrectal	O
ultrasonography	I:C0373345
biopsy	B:C0005558
cohort	O
,	O
but	O
only	O
2.5	O
%	O
in	O
the	O
post	O
-	O
MRI	O
biopsy	I:C0456854
cohort	O
(	O
P	O
=	O
0.021	O
)	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
Gleason	O
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
carcinoma	O
in	O
their	O
prostatectomy	O
specimen	O
was	O
11.2	O
%	O
in	O
the	O
post	O
-	O
transrectal	O
ultrasonography	I:C0373345
biopsy	O
cohort	B:C0599755
,	O
but	O
only	O
2.5	O
%	O
in	O
the	O
post	O
-	O
MRI	O
biopsy	I:C0456854
cohort	O
(	O
P	O
=	O
0.021	O
)	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
Gleason	O
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
carcinoma	O
in	O
their	O
prostatectomy	O
specimen	O
was	O
11.2	O
%	O
in	O
the	O
post	O
-	O
transrectal	O
ultrasonography	I:C0373345
biopsy	O
cohort	O
,	O
but	O
only	O
2.5	O
%	O
in	O
the	O
post	O
-	O
MRI	B:C0456854
biopsy	I:C0456854
cohort	O
(	O
P	O
=	O
0.021	O
)	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
Gleason	O
grade	I:C3203027
3	O
+	O
3	O
=	O
6	O
carcinoma	O
in	O
their	O
prostatectomy	O
specimen	O
was	O
11.2	O
%	O
in	O
the	O
post	O
-	O
transrectal	O
ultrasonography	I:C0373345
biopsy	O
cohort	O
,	O
but	O
only	O
2.5	O
%	O
in	O
the	O
post	O
-	O
MRI	O
biopsy	I:C0456854
cohort	B:C0599755
(	O
P	O
=	O
0.021	O
)	O
.	O

MRI	B:C0456854
-	I:C0456854
guided	I:C0456854
transgluteal	O
prostate	O
biopsy	I:C0194804
has	O
a	O
high	O
detection	O
rate	O
for	O
high	O
-	I:C1512441
risk	I:C1512441
carcinomas	I:C1512441
,	O
while	O
the	O
risk	O
of	O
detecting	O
clinically	O
insignificant	O
carcinomas	O
appears	O
to	O
be	O
reduced	O
.	O

MRI	O
-	I:C0456854
guided	I:C0456854
transgluteal	B:C0444462
prostate	O
biopsy	I:C0194804
has	O
a	O
high	O
detection	O
rate	O
for	O
high	O
-	I:C1512441
risk	I:C1512441
carcinomas	I:C1512441
,	O
while	O
the	O
risk	O
of	O
detecting	O
clinically	O
insignificant	O
carcinomas	O
appears	O
to	O
be	O
reduced	O
.	O

MRI	O
-	I:C0456854
guided	I:C0456854
transgluteal	O
prostate	B:C0194804
biopsy	I:C0194804
has	O
a	O
high	O
detection	O
rate	O
for	O
high	O
-	I:C1512441
risk	I:C1512441
carcinomas	I:C1512441
,	O
while	O
the	O
risk	O
of	O
detecting	O
clinically	O
insignificant	O
carcinomas	O
appears	O
to	O
be	O
reduced	O
.	O

MRI	O
-	I:C0456854
guided	I:C0456854
transgluteal	O
prostate	O
biopsy	I:C0194804
has	O
a	O
high	O
detection	B:C1511790
rate	O
for	O
high	O
-	I:C1512441
risk	I:C1512441
carcinomas	I:C1512441
,	O
while	O
the	O
risk	O
of	O
detecting	O
clinically	O
insignificant	O
carcinomas	O
appears	O
to	O
be	O
reduced	O
.	O

MRI	O
-	I:C0456854
guided	I:C0456854
transgluteal	O
prostate	O
biopsy	I:C0194804
has	O
a	O
high	O
detection	O
rate	O
for	O
high	B:C1512441
-	I:C1512441
risk	I:C1512441
carcinomas	I:C1512441
,	O
while	O
the	O
risk	O
of	O
detecting	O
clinically	O
insignificant	O
carcinomas	O
appears	O
to	O
be	O
reduced	O
.	O

MRI	O
-	I:C0456854
guided	I:C0456854
transgluteal	O
prostate	O
biopsy	I:C0194804
has	O
a	O
high	O
detection	O
rate	O
for	O
high	O
-	I:C1512441
risk	I:C1512441
carcinomas	I:C1512441
,	O
while	O
the	O
risk	O
of	O
detecting	B:C1511790
clinically	O
insignificant	O
carcinomas	O
appears	O
to	O
be	O
reduced	O
.	O

MRI	O
-	I:C0456854
guided	I:C0456854
transgluteal	O
prostate	O
biopsy	I:C0194804
has	O
a	O
high	O
detection	O
rate	O
for	O
high	O
-	I:C1512441
risk	I:C1512441
carcinomas	I:C1512441
,	O
while	O
the	O
risk	O
of	O
detecting	O
clinically	O
insignificant	B:C1273937
carcinomas	O
appears	O
to	O
be	O
reduced	O
.	O

MRI	O
-	I:C0456854
guided	I:C0456854
transgluteal	O
prostate	O
biopsy	I:C0194804
has	O
a	O
high	O
detection	O
rate	O
for	O
high	O
-	I:C1512441
risk	I:C1512441
carcinomas	I:C1512441
,	O
while	O
the	O
risk	O
of	O
detecting	O
clinically	O
insignificant	O
carcinomas	B:C0007097
appears	O
to	O
be	O
reduced	O
.	O

This	O
may	O
by	O
itself	O
lead	O
to	O
a	O
reduction	O
of	O
unnecessary	B:C0376707
prostatectomies	I:C0376707
.	O

Overtreatment	B:C4046039
may	O
be	O
further	O
avoided	O
by	O
better	O
applicability	O
of	O
molecular	O
testing	I:C0752096
to	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
because	O
of	O
the	O
excessive	O
amount	O
of	O
tissue	O
available	O
for	O
analysis	O
,	O
especially	O
in	O
patients	O
with	O
potential	O
low	O
-	O
risk	O
carcinomas	O
.	O

Overtreatment	O
may	O
be	O
further	O
avoided	O
by	O
better	O
applicability	O
of	O
molecular	B:C0752096
testing	I:C0752096
to	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
because	O
of	O
the	O
excessive	O
amount	O
of	O
tissue	O
available	O
for	O
analysis	O
,	O
especially	O
in	O
patients	O
with	O
potential	O
low	O
-	O
risk	O
carcinomas	O
.	O

Overtreatment	O
may	O
be	O
further	O
avoided	O
by	O
better	O
applicability	O
of	O
molecular	O
testing	I:C0752096
to	O
MRI	B:C0456854
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
because	O
of	O
the	O
excessive	O
amount	O
of	O
tissue	O
available	O
for	O
analysis	O
,	O
especially	O
in	O
patients	O
with	O
potential	O
low	O
-	O
risk	O
carcinomas	O
.	O

Overtreatment	O
may	O
be	O
further	O
avoided	O
by	O
better	O
applicability	O
of	O
molecular	O
testing	I:C0752096
to	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
because	O
of	O
the	O
excessive	O
amount	O
of	O
tissue	B:C0027656
available	O
for	O
analysis	O
,	O
especially	O
in	O
patients	O
with	O
potential	O
low	O
-	O
risk	O
carcinomas	O
.	O

Overtreatment	O
may	O
be	O
further	O
avoided	O
by	O
better	O
applicability	O
of	O
molecular	O
testing	I:C0752096
to	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
because	O
of	O
the	O
excessive	O
amount	O
of	O
tissue	O
available	O
for	O
analysis	B:C0936012
,	O
especially	O
in	O
patients	O
with	O
potential	O
low	O
-	O
risk	O
carcinomas	O
.	O

Overtreatment	O
may	O
be	O
further	O
avoided	O
by	O
better	O
applicability	O
of	O
molecular	O
testing	I:C0752096
to	O
MRI	O
-	I:C0456854
guided	I:C0456854
biopsies	I:C0456854
because	O
of	O
the	O
excessive	O
amount	O
of	O
tissue	O
available	O
for	O
analysis	O
,	O
especially	O
in	O
patients	O
with	O
potential	O
low	O
-	O
risk	O
carcinomas	B:C0007097
.	O

